ishikawa kiyohito

Twenty-one adult male outpatients with gonococcal (GUC) or chlamydial (NGU), and gonococcal/chlamydial (GCU/NGU) urethritis were treated with temafloxacin.<BR>It was given at a dose of 300-600 600 mg a day for 4-28 28 days (8.7+5.7 days). Eradication of the organisms was obtained for GCU in 14/14 (100%), NGU 3/3 (100%), and GCU/NGU 4/4 (100%). Clinically, the drug proved to be highly effective for male urethritis, and it was well tolerated by all patients treated.

Temafloxacin (TMFX) was administered at a dose of 150mg, b. i. d., for 3 days, in 15 clinical cases of acute uncomplicated cystitis. The clinical response rate was 100% (excellent 66.7%, moderate 100%), and the bacteriological cure rate was also 100%. Twenty-two patients with complicated urinary tract infections were treated with a dose of 150mg, b. i. d., for 5 days.<BR>An overall clinical efficacy rate of 66.7% was achieved based on Japanese UTI criteria. The bacteriological eradication was obtained in 21 out of 27 cases (77.8%).<BR>Regarding safety profile, no abnormal clinical values were detected among the laboratory test data. Side effects were found in 2 patients, peripheral neuropathy in 1 patient and a sensation of burning in the chest, in the other, however they both disappeared within a few days after discontinuation of the drug.

To evaluate the efficacy and safety of the novel injectable cephem cefozopran (CZOP), this drug was administered to 31 patients with infection in the field of urology. The subjects consisted of 28 patients with UTI (simple in 5 and complicated in 23) and 3 patients with bacterial prostatitis (acute in 2 and chronic in 1).<BR>The drug was administered by drip infusion in doses of 0.5 to 1.0 g once to three times daily for 3 to 15 days.<BR>According to the drug effect evaluation criteria for UTI, the response was classified as excellent in 3 of 13 patients with simple UTI and good or excellent in 16 of 19 patients with complicated UTI, the overall efficacy rate being 84.2 %. The drug benefited 2 of 3 patients with prostatitis.<BR>As for the safety of the drug, none of the patients treated had any side effects. As for the laboratory tests, a slight elevation in S-GPT was noted, and an elevation in eosinophils and the transient appearance of atypical lymphocytes were observed in 1 case each.

Eighty patients with urological infections were treated with the novel oral cephem antibiotic, ME127, in doses of 2 to 6 mg/day, and the following results were obtained. The drug was effective in 1% of the 15 patients with acute uncomplicated cystitis and in 69.4% of the 36 patients with chronic complicated urinary tract infection according to the criteria proposed by the Japanese UTI Committee, and in 8 out of 9 male patients with urethritis and in the 1 patient with chronic prostatitis. As to side effects of the drug, two patients had loose stools and 1 had diarrhea. Regarding laboratory finding, 7 patients elevated GOT and GPT, but these values normalized within a week after completion of therapy.

尿中THG(Tamm Horsfall Glycoprotein)をELISA法を用いて測定した。従来の測定法では,抗体試薬を自家調整するために時間と労力が必要であった。これを簡略化するために,市販ポリクローナル抗体を使用したところ,同時に大量の検体が短時間で測定でき,その精度は従来の方法に比して遜色がなかった

One hundred and twenty three strains of Escherichia coli isolated from the urine of patients with urogenital infections and 55 strains isolated from the fecal samples of healthy individuals were assayed for 0 antigen and hemolysin production as virulence factors, and for pilus type and in vitro tests of adhesion to human exfoliated uroepithelial cells as colonization factors. The incidence of MS pili in Escherichia coli isolated from patients with acute uncomplicated cystitis, chronic complicated cystitis, acute uncomplicated pyelonephritis and acute prostatitis was 60.9%, 22.7%, 87.5%, 68.2% and 30.9%, respectively. The incidence of P pili was 69.7%, 51.2%, 62.5%, 54.5% and 25.5%, respectively. The strains showing haemolysin production had MS pili and P pili, which show strong virulence. MS pili strains and P pili strains isolated from the patients with acute uncomplicated cystitis and acute uncomplicated pyelonephritis adhered to human exfoliated uroepithelial cells well. Consequently, the pilus type might be the most significant colonization factor in uncomplicated urogenital infection which is shown by the normal defense mechanism in host side.

急性単純性膀胱炎に対するcefaclor少量投与療法(1日25 mg)の有効性,安全性について,同剤の常用量(1日500 mg)およびofloxacinの常用量(1日200 mg)を対照にして比較検討した.3日間経口投与後の有効率は各群ともに100%であり,臨床効果には有意差はなかった.各薬剤の常用量投与群では糞便中の尿路感染症起炎菌となりうる菌(E. coli)の10%に耐性菌が出現したが,少量投与群では耐性菌はみなかった.著者等の治療法では,腸内細菌叢の中に耐性菌をみることなく十分な効果が期待できた

We performed a clinical study on fleroxacin, a newly developed quinolone derivative, with the following results.<BR>1. Diffusion into prostatic fluid (PF)<BR>The concentration of fleroxacin in PFs, which were collected 1.0-1.5h after a 200 mg administration, ranged from 0.04-0.21&mu;g/ml (4 specimens from 2 patients).<BR>2. Clinical results<BR>Fleroxacin was used in treating 40 patients at doses of 200-600mg a day (400mg, in 2 divided doses, as a rule) for 3-28 days (in many cases 5-14 days).<BR>1) Urinary tract infection<BR>(a) Acute uncomplicated cystitis: all five patients, assessed by the Japanese UTI Committee's criteria, were completely cured after 3 day's administration.<BR>(b) Chronic complicated diseases: of 21 cases, efficacy in 14 (66.7%) was evaluated as excellent or moderate according to the Japanese UTI Committee's criteria.<BR>(c) Genital infection: efficacy in two cases of chronic prostatitis was good and poor. Of two cases of chronic epididymitis (non-chlamydial), the response was good in both after 10-14 day's treatment.<BR>3. Side effects<BR>1) Clinical abnormal values: a transient, mild elevation of BUN and s-Cr was observed in one case.<BR>2) Subjective side effects: there were four cases (six incidences) of side effects probably due to the drug administration: vomiting, headache, disturbed sleep/irritating feeling, and disturbed sleep/light-headed feeling, in one case each.<BR>Except in the case of vomiting, administration was continued. After therapy was completed these side effects spontaneously disappeared within 1-2 days.<BR>We consider that fleroxacin's long half life (about 10 h) makes it useful in treating UTI and genito-urinary tract infections with once daily administration.